Literature DB >> 11226131

Analysis of the muscarinic receptor subtype mediating inhibition of the neurogenic contractions in rabbit isolated vas deferens by a series of polymethylene tetra-amines.

R Budriesi1, S Cacciaguerra, R D Toro, M L Bolognesi, A Chiarini, A Minarini, M Rosini, S Spampinato, V Tumiatti, C Melchiorre.   

Abstract

The pharmacological characteristics of the presynaptic muscarinic receptor subtype, which mediates inhibition of the neurogenic contractions in the prostatic portion of rabbit vas deferens, have been investigated by using a series of polymethylene tetra-amines, which were selected for their ability to differentiate among muscarinic receptor subtypes. It was found that all tetra-amines antagonized McN-A-343-induced inhibition in electrically stimulated rabbit vas deferens in a competitive manner and with affinity values (pA:(2)) ranging between 6.27+/-0.09 (spirotramine) and 8.51+/-0.02 (AM170). Competition radioligand binding studies, using native muscarinic receptors from rat tissues (M(1), cortex; M(2), heart; M(3), submaxillary gland) or from NG 108-15 cells (M(4)) and human cloned muscarinic M(1)-M(4) receptors expressed in CHO-K1 cells, were undertaken with the same tetra-amines employed in functional assays. All antagonists indicated a one-site fit. The affinity estimates (pK:(i)) of tetra-amines calculated in binding assays using native receptors were similar to those obtained using cloned receptors. Among these compounds some displayed selectivity between muscarinic receptor subtypes, indicating that they may be valuable tools in receptor characterization. Spirotramine was selective for M(1) receptors versus all other subtypes (pK:(i) native: M(1), 7.32+/-0.10; M(2), 6.50+/-0.11; M(3), 6.02+/-0.13; M(4), 6.28+/-0.16; pK:(i) cloned: M(1), 7.69+/-0.08; M(2), 6.22+/-0.14; M(3), 6.11+/-0.16; 6.35+/-0.11) whereas CC8 is highly selective for M(2) receptors versus the other subtypes (pK:(i) native: M(1), 7.50+/-0.04; M(2), 9.01+/-0.12; M(3), 6.70+/-0.08; M(4), 7.56+/-0.04; pK:(i) cloned: M(1), 7.90+/-0.20; M(2), 9.04+/-0.08; M(3), 6.40+/-0.07; M(4), 7.40+/-0.04). Furthermore, particularly relevant for this investigation were tetra-amines dipitramine and AM172 for their ability to significantly differentiate M(1) and M(4) receptors. The apparent affinity values (pA:(2)) obtained for tetra-amines in functional studies using the prostatic portion of rabbit vas deferens correlated most closely with the values (pK:(i)) obtained at either native or human recombinant muscarinic M(4) receptors. This supports the view that the muscarinic receptor mediating inhibition of neurogenic contractions of rabbit vas deferens may not belong to the M(1) type but rather appears to be of the M(4) subtype.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11226131      PMCID: PMC1572637          DOI: 10.1038/sj.bjp.0703891

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  30 in total

1.  Tricyclic compounds as selective muscarinic receptor antagonists. 3. Structure-selectivity relationships in a series of cardioselective (M2) antimuscarinics.

Authors:  W W Engel; W G Eberlein; G Mihm; R Hammer; G Trummlitz
Journal:  J Med Chem       Date:  1989-08       Impact factor: 7.446

2.  Differential blockade of muscarinic receptor subtypes by polymethylene tetraamines. Novel class of selective antagonists of cardiac M-2 muscarinic receptors.

Authors:  C Melchiorre; A Cassinelli; W Quaglia
Journal:  J Med Chem       Date:  1987-01       Impact factor: 7.446

3.  Analysis of radioligand binding experiments. A collection of computer programs for the IBM PC.

Authors:  G A McPherson
Journal:  J Pharmacol Methods       Date:  1985-11

4.  Stereoselective recognition of the enantiomers of phenglutarimide and of six related compounds by four muscarinic receptor subtypes.

Authors:  M Waelbroeck; S Lazareno; O Pfaff; T Friebe; M Tastenoy; E Mutschler; G Lambrecht
Journal:  Br J Pharmacol       Date:  1996-12       Impact factor: 8.739

5.  Ligand: a versatile computerized approach for characterization of ligand-binding systems.

Authors:  P J Munson; D Rodbard
Journal:  Anal Biochem       Date:  1980-09-01       Impact factor: 3.365

6.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

7.  Muscarinic M1- and M2-receptors mediating opposite effects on neuromuscular transmission in rabbit vas deferens.

Authors:  M Eltze
Journal:  Eur J Pharmacol       Date:  1988-07-07       Impact factor: 4.432

8.  Affinity and selectivity of biperiden enantiomers for muscarinic receptor subtypes.

Authors:  M Eltze; V Figala
Journal:  Eur J Pharmacol       Date:  1988-12-06       Impact factor: 4.432

9.  A cDNA cloning vector that permits expression of cDNA inserts in mammalian cells.

Authors:  H Okayama; P Berg
Journal:  Mol Cell Biol       Date:  1983-02       Impact factor: 4.272

10.  Methoctramine, a polymethylene tetraamine, differentiates three subtypes of muscarinic receptor in direct binding studies.

Authors:  A D Michel; R L Whiting
Journal:  Eur J Pharmacol       Date:  1988-01-05       Impact factor: 4.432

View more
  3 in total

1.  Cholinergic interneurons control the excitatory input to the striatum.

Authors:  Pavel Pakhotin; Enrico Bracci
Journal:  J Neurosci       Date:  2007-01-10       Impact factor: 6.167

2.  Pharmacological characterization of muscarinic receptor subtypes mediating vasoconstriction of human umbilical vein.

Authors:  Virginia Andrea Pujol Lereis; Francisco Javier Hita; Mauro Darío Gobbi; Marcela Gomez Verdi; María Cecilia Rodriguez; Rodolfo Pedro Rothlin
Journal:  Br J Pharmacol       Date:  2006-03       Impact factor: 8.739

3.  Effects of muscarinic toxins MT1 and MT2 from green mamba on different muscarinic cholinoceptors.

Authors:  Alan L Harvey; Edgar Kornisiuk; Karen N Bradley; Carlos Cerveñansky; Rosario Durán; Martin Adrover; Gonzalo Sánchez; Diana Jerusalinsky
Journal:  Neurochem Res       Date:  2002-11       Impact factor: 3.996

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.